Company news
Oxford Biodynamics Plc (LSE:OBD) news
Oxford Biodynamics Plc news releases on 6ix. Latest, Jul 25, 2024: OBD pursuing EpiSwitch as companion diagnostics
Press releases — page 2
OBD pursuing EpiSwitch as companion diagnostics
July 25, 2024
Grant of Options
June 21, 2024
Half-year Report
June 18, 2024
OBD's PSE test to be used in NCI trial
June 6, 2024
OBD develops multi-cancer diagnostic test for dogs
June 4, 2024
OBD partners with Goodbody Clinic on PSE test
May 23, 2024
OBD partners with The London Clinic for PSE & CiRT
May 21, 2024
OBD and King's College London collaborate on RA
May 16, 2024
Results of GM
April 3, 2024
OBD opens UK clinical testing facility
April 3, 2024
Results of Fundraising
March 14, 2024
PrimaryBid Offer
March 13, 2024
Annual Report & Accounts
February 22, 2024
OBD strengths commercial leadership
November 8, 2023
Oxford BioDynamics Plc - Bupa UK to cover EpiSwitch CiRT for customers with cancer
October 19, 2023
Bupa UK to cover EpiSwitch® CiRT for customers
October 18, 2023
Oxford BioDynamics receives reimbursement code for EpiSwitch Prostate Screening Test
October 4, 2023
OBD receives reimbursement code for PSE test
October 3, 2023
Oxford Biodynamics launches the 94% accurate EpiSwitch Prostate Screening blood test for men with prostate cancer risk in the US and UK
September 27, 2023
OBD launches 94% accurate PSE test in US and UK
September 26, 2023
Amendment: Director/PDMR Shareholding
September 1, 2023
Result of General Meeting
August 18, 2023
Results of PrimaryBid Offer
August 4, 2023
Notice of Interim Results and Investor Webinar
May 16, 2023
CiRT expanded validation for ICI immunotherapies
May 15, 2023
US PACT Award for prognosis test for IOrelated HPD
May 2, 2023
Business update for PSE and CiRT tests
April 5, 2023
AIM Rule 17 Schedule 2(g) Update
March 15, 2023
Publication of FY22 Annual Report
March 3, 2023
OBD Prostate Screening EpiSwitch Blood Test Update
February 6, 2023
Notice of FY22 Results and Investor Webinar
December 21, 2022
OBD in San Francisco for JPM Healthcare conf 2023
December 19, 2022
Initial assessment of EpiSwitch assay in ALS trial
December 16, 2022
Exercise period extension - existing share options
December 14, 2022
Discussion about EpiSwitch CiRT at Key Summit
November 21, 2022
Second Price Monitoring Extn
November 18, 2022
Price Monitoring Extension
November 18, 2022
Total Voting Rights
November 1, 2022
Result of General Meeting, Director/PDMR Dealings
October 27, 2022
Result of Open Offer
October 25, 2022
Proposed Placing and Open Offer
October 7, 2022
US Reimbursement Code for CiRT now available
October 3, 2022
ESMO data highlights unique benefit of EpiSwitch
September 15, 2022
CiRT highlighted at ESMO 2022 presentation
September 6, 2022
US reimbursement code for EpiSwitch® CiRT
July 5, 2022
EpiSwitch® CiRT now available in the UK
June 21, 2022
Notice of Interim Results Webinar
June 17, 2022
OBD EpiSwitch® CiRT well received at ASCO 2022
June 14, 2022
OBD to present CiRT clinical utility data at ASCO
May 5, 2022
Results of Annual General Meeting
March 30, 2022